

For Public Release
NZX Limited
Wellington

29 March 2023

Cannasouth Limited Releases Annual Report for the Year Ended 31 December 2022

Cannasouth Limited (NZX : CBD, Cannasouth), today released its Annual Report for the year ended 31 December 2022.

Included with this announcement are the following documents:

- 2022 Annual Report
- Results Announcement Form

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO

Email: mark.lucas@cannasouth.co.nz

Mobile: 021 484 649

Colin Foster

CFO / Company Secretary

Email: colin.foster@cannasouth.co.nz

Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products will be produced under GxP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd and Cannasouth Cultivation Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>